Stege R, Tribukait B, Lundh B, Carlström K, Pousette A, Hasenson M
Department of Urology, Karolinska Institutet, Huddinge University Hospital, Sweden.
J Urol. 1992 Sep;148(3):833-7. doi: 10.1016/s0022-5347(17)36736-8.
The prognostic value of deoxyribonucleic acid (DNA) flow cytometry, cytological grading and the direct assay of prostate specific antigen (PSA) in the material of fine needle aspirates was studied in 67 consecutive patients with newly detected prostatic carcinoma. All patients were hormonally treated (castration in 27 and luteinizing hormone-releasing hormone agonist or parenteral estrogens in 40). The patients were followed for a minimum of 2 years. PSA was analyzed in the biopsy material by a direct radioimmunoassay and related to the total amount of DNA. In parallel biopsies DNA ploidy using flow cytometry and cytological grade were established. Patients with a geometric mean value of greater than or equal to 0.12 microgram. PSA/microgram. DNA had a progression rate of 7%, compared to 59% for those with less than 0.12 microgram. PSA/microgram. DNA. In Cox multivariate analysis cytology and tissue PSA content were the most important factors in expressing the difference for interval to progression in hormonally treated patients.
对67例新诊断为前列腺癌的连续患者，研究了细针穿刺抽吸物中脱氧核糖核酸（DNA）流式细胞术、细胞学分级及前列腺特异性抗原（PSA）直接检测的预后价值。所有患者均接受了激素治疗（27例行去势术，40例行促黄体生成素释放激素激动剂或胃肠外雌激素治疗）。对患者进行了至少2年的随访。通过直接放射免疫分析法分析活检材料中的PSA，并将其与DNA总量相关联。同时采用流式细胞术确定活检组织的DNA倍体及细胞学分级。PSA/μg.DNA几何均值大于或等于0.12μg的患者，疾病进展率为7%，而PSA/μg.DNA小于0.12μg的患者，疾病进展率为59%。在Cox多变量分析中，细胞学及组织PSA含量是激素治疗患者中表达疾病进展间隔差异的最重要因素。
